Research is being conducted on targeting CDKs in cancer therapy, with advancements being made in PROTACs and molecular glues. Studies are exploring various approaches, including protein kinase inhibitors, phosphorylation targeting strategies, and dual-targeting CDKs regulators. The developments aim to improve cancer therapy by degrading oncogenic drivers and targeting previously "undruggable" proteins.